Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Central University Hospital of Nice

Highlights in LR-MDS at the ASH 2023 meeting 1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML 1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT 2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Unmet needs in high-risk MDS and ongoing trials in the field 1:42
Unmet needs in high-risk MDS and ongoing trials in the field
Thomas Cluzeau • 12 Jun 2022
The role of immunotherapy in the AML treatment landscape 3:47
The role of immunotherapy in the AML treatment landscape
Thomas Cluzeau • 12 Jun 2022
Factors to consider when treating AML and the importance of communicating with patients 1:31
Factors to consider when treating AML and the importance of communicating with patients
Thomas Cluzeau • 12 Jun 2022
How MRD assessment can inform treatment decisions in AML 1:44
How MRD assessment can inform treatment decisions in AML
Thomas Cluzeau • 12 Jun 2022
Phase II trial of eprenetapopt plus azacitidine: long-term follow up 1:24
Phase II trial of eprenetapopt plus azacitidine: long-term follow up
Thomas Cluzeau • 13 Dec 2021
Major trial outcomes at ASH 2021: PANTHER, AGILE, and LACEWING 1:59
Major trial outcomes at ASH 2021: PANTHER, AGILE, and LACEWING
Thomas Cluzeau • 13 Dec 2021
IDIOME: ivosidenib in IDH1 mutant MDS 1:32
IDIOME: ivosidenib in IDH1 mutant MDS
Thomas Cluzeau • 13 Dec 2021
Updates on CPX-351: real world experiences and studies in MDS 1:48
Updates on CPX-351: real world experiences and studies in MDS
Thomas Cluzeau • 13 Dec 2021
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML 2:58
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML
Thomas Cluzeau • 20 Sep 2021
AML treatment: ASH 2020 and beyond 4:54
AML treatment: ASH 2020 and beyond
Thomas Cluzeau • 9 Dec 2020
SY-1425 plus azacitidine treatment in AML 2:11
SY-1425 plus azacitidine treatment in AML
Thomas Cluzeau • 9 Dec 2020
The future of MDS management 1:04
The future of MDS management
Thomas Cluzeau • 30 Sep 2020
The 2020 highlights in MDS 4:47
The 2020 highlights in MDS
Thomas Cluzeau • 30 Sep 2020
The content of VJHemOnc is intended for healthcare professionals